{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"18","value":"6"},{"groupId":"OG001","lowerLimit":"15","upperLimit":"85","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Incidence of TRM at 6 months","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients aged 3-55 years will be conditioned with cyclophosphamide (CY) 120 mg/kg total dose, fludarabine (FLU) 75 m/m2 total dose and total body irradiation (TBI) 1320 cGy total dose as well as tacrolimus (Tac) and mycophenolate mofetil (MMF) immunoprophylaxis and granulocyte-colony stimulating factor (G-CSF)","id":"OG000","title":"FLU, CY, TBI + MGTA-456 Infusion"},{"description":"All young children \\<3 years of age at the time of diagnosis will receive MGTA-456 on the day of transplantation after a non-TBI containing myeloablative conditioning as TBI may have a damaging effect on brain development in the very young child. All patients aged 0-3 years will be conditioned with busulfan (BU), FLU and melphalan (MEL) as well as Tac/MMF immunoprophylaxis and G-CSF","id":"OG001","title":"BU,FLU, MEL + MGTA-456 Infusion"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 Months","title":"Treatment Related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}